Resumen de Análisis de los cambios y suspensión de tratamientos biológicos en artritis reumatoide, espondilitis anquilosante y artritis psoriásica
Mª I. Seguí Gregori, Mercedes Franco Donat, Amparo Rocher Milla, José Ivorra Cortés, Juan Antonio Castellano Cuesta
Objectives: To analyze the causes for change and suspension of tumor necrosis factor-alpha (anti-TNF) inhibitors in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis. And, to evaluate their adverse drug reactions (ADRs). Method: Observational descriptive study from January 2006 to December 2007. We analyzed clinical records and used the software program G-Stat 2.0®. Results: 69 patients were included in the study. 73.9% of them received monotherapy, 23.2% changed to a second medication, and 2.9% changed to a third, without any significant differences when associating methotrexate. Neither age nor time until the beginning of treatment did influence. ADRs appeared in 33.4% of those patients treated with infliximab, 46.7% of those treated with etanercept and 63.6% of those treated with adalimumab. Conclusions: The most frequent causes for treatment change or suspension were either inefficacy or the appearance of ADRs. The prevalence of suspension was similar for the three drugs. Infliximab was primarily suspended because of inefficacy, and the treatment with adalimumab caused the most ADRs
